IP Library Granted Patent US 8,962,693
Granted Patent B2
US 8,962,693 · App. 13/970,026 · Granted Feb 24, 2015

Method for the treatment or prevention of lower urinary tract symptoms

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,962,693
App. No.
13/970,026
Granted
Feb 24, 2015
Kind
B2
Abstract

This invention concerns a method for treatment or prevention of lower urinary tract symptoms with or without pelvic pain in an individual, said method comprising administering to the individual an effective amount of a selective estrogen receptor modulator, or an isomer, isomer mixture or a pharmaceutically acceptable salt thereof.

Claims (8)

1. A method for treatment of obstructive lower urinary tract symptoms in a male individual, said method comprising administering to the individual an effective amount of (Z)-2-{2-[4-(4-Chloro-1,2-diphenylbut-1-enyl)phenoxy]ethoxy}ethanol (fispemifene), or an isomer, isomer mixture or a pharmaceutically acceptable salt thereof, wherein the obstructive lower urinary tract symptoms are caused by detrusor urethral sphincter dyssynergia.

2. The method according to claim 1 , wherein the detrusor urethral sphincter dyssynergia comprises bladder neck dyssynergia, external sphincter pseudodyssynergia, or Hinman syndrome.

3. The method according to claim 1 , wherein the obstructive lower urinary tract symptoms comprise hesitance, poor urinary stream, terminal dripping, or incomplete bladder emptying.

4. The method according to claim 2 , wherein the obstructive lower urinary tract symptoms comprise hesitance, poor urinary stream, terminal dripping, or incomplete bladder emptying.

5. The method according to claim 1 , wherein the method comprises administering to the individual an effective amount of fispemifene.

6. The method according to claim 2 , wherein the method comprises administering to the individual an effective amount of fispemifene.

7. The method according to claim 3 , wherein the method comprises administering to the individual an effective amount of fispemifene.

8. The method according to claim 4 , wherein the method comprises administering to the individual an effective amount of fispemifene.

Assignments (2)
CHANGE OF NAME Recorded May 22, 2014
From: HORMOS MEDICAL CORPORATION
To: HORMOS MEDICAL LTD.
Reel/Frame 032986/0510 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 20, 2013
From: SANTTI, RISTO; STRENG, TOMI
To: HORMOS MEDICAL CORPORATION
Reel/Frame 031041/0510 →